Pharma giant Lupin declared that it has gotten approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to showcase a generic variant of Eli Lilly and Company’s Adcirca Tablets, 20 mg.
Lupin’s Tadalafil Tablets USP, 20 mg is the generic form of Eli Lilly and Company’s Adcirca Tablets, 20 mg. It is demonstrated for the treatment of aspiratory blood vessel hypertension (PAH) (WHO Group 1) to enhance exercise capacity.
Tadalafil Tablets, 20 mg had yearly offers of around USD 474.3 million in the US (IQVIA MAT December 2018).
About Lupin Limited:
Lupin Ltd is public company based in Mumbai. In terms of market capitalization, it is the 12th largest company and 8th largest in terms of generic pharmaceutical company. It areas include pediatrics, cardiovascular, anti-infective, diabetes, asthma and anti-tuberculosis.